These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 16426877)
1. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Filitz J; Griessinger N; Sittl R; Likar R; Schüttler J; Koppert W Eur J Pain; 2006 Nov; 10(8):743-8. PubMed ID: 16426877 [TBL] [Abstract][Full Text] [Related]
2. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Likar R; Kayser H; Sittl R Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176 [TBL] [Abstract][Full Text] [Related]
3. Plasma buprenorphine concentrations after the application of a 70 microg/h transdermal patch in dogs. Preliminary report. Andaluz A; Moll X; Ventura R; Abellán R; Fresno L; García F J Vet Pharmacol Ther; 2009 Oct; 32(5):503-5. PubMed ID: 19754919 [TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
5. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients. Griessinger N; Sittl R; Likar R Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522 [TBL] [Abstract][Full Text] [Related]
6. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain]. Tschirner M; Ritzdorf I; Brünjes R MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217 [TBL] [Abstract][Full Text] [Related]
7. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363 [TBL] [Abstract][Full Text] [Related]
8. Transdermal buprenorphine in pain management--experiences from clinical practice: Five case studies. Louis F Int J Clin Pract; 2006 Oct; 60(10):1330-4. PubMed ID: 16981980 [TBL] [Abstract][Full Text] [Related]
9. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study. Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study. Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544 [TBL] [Abstract][Full Text] [Related]
11. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
12. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481 [TBL] [Abstract][Full Text] [Related]
13. Transdermal buprenorphine in cancer pain and palliative care. Sittl R Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218 [TBL] [Abstract][Full Text] [Related]
14. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Koltzenburg M; Pokorny R; Gasser UE; Richarz U Pain; 2006 Dec; 126(1-3):165-74. PubMed ID: 16901645 [TBL] [Abstract][Full Text] [Related]
15. Challenging the equipotency calculation for transdermal buprenorphine: four case studies. Likar R; Krainer B; Sittl R Int J Clin Pract; 2008 Jan; 62(1):152-6. PubMed ID: 18173815 [TBL] [Abstract][Full Text] [Related]
16. Buprenorphine TDS: use in daily practice, benefits for patients. Radbruch L Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of buprenorphine after intravenous administration in the mouse. Yu S; Zhang X; Sun Y; Peng Y; Johnson J; Mandrell T; Shukla AJ; Laizure SC J Am Assoc Lab Anim Sci; 2006 May; 45(3):12-6. PubMed ID: 16642964 [TBL] [Abstract][Full Text] [Related]
18. Buprenorphine exposure in infants of opioid-dependent mothers at birth. Bartu AE; Ilett KF; Hackett LP; Doherty DA; Hamilton D Aust N Z J Obstet Gynaecol; 2012 Aug; 52(4):342-7. PubMed ID: 22428721 [TBL] [Abstract][Full Text] [Related]
19. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Dagtekin O; Gerbershagen HJ; Wagner W; Petzke F; Radbruch L; Sabatowski R Anesth Analg; 2007 Nov; 105(5):1442-8, table of contents. PubMed ID: 17959980 [TBL] [Abstract][Full Text] [Related]
20. Buprenorphine and the transdermal system: the ideal match in pain management. Budd K Int J Clin Pract Suppl; 2003 Feb; (133):9-14; discussion 23-4. PubMed ID: 12665118 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]